Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The clinical data of 18 patients diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) from Department of Neurology of Peking Union Medical College Hospital from June 2016 to January 2018 were retrospectively analyzed and P/Q-type voltage-gated calcium channel (VGCC) antibodies were detected by radioimmunoprecipitation assay. The VGCC antibody (Ab)-positive rate of LEMS was 15/18, and there were no significant differences in gender, age, disease severity, and tumor prevalence. The disease course was shorter in the antibody-positive group (1.9 years vs 7.6 years, P=0.04), and the clinical manifestation was more complicated in the group with a higher VGCC-Ab. There was a significant correlation between VGCC-Ab and recurrence rate(τ=0.48, P=0.02).

Original publication




Journal article


National Medical Journal of China

Publication Date





2617 - 2620